Senior Biotech AnalystÂ Charles C. Duncan, PhD moderated “Tripping Our Way to a New Treatment Paradigm for Psychiatric Disorders – Intermittent Therapy vs. Chronic Treatment.” The panel featuredÂ Srinivas Rao, CSO ofÂ atai Life Sciences,Â Doug Drysdale, CEO ofÂ Cybin Inc.,Â Robert Barrow, CEO ofÂ MindMed, andÂ Nathan Bryson, PhD, CSO ofÂ Reunion Neuroscience, and Raj Mehra, PhD, CEO ofÂ Seelos Therapeutics, Inc.
• The panel kicked off with identifying considerable unmet needs in the mental health space (MDD, anxiety, acute suicidality) and why the current treatment paradigm are largely failing these patients
• Intermittent dosing of psychedelics, especially if therapeutic benefit lasts for 3 months, could reduce the economic burden in the end and usher in a new psychiatric treatment paradigm
• Sample size, timing of endpoints, and redosing schedule (if included) are important considerations when designing a robust clinical trial
• Procuring sufficient IP could be difficult for psychedelics but each panelist has unique variants or novel compounds that enable patentability